Therapeutic drug monitoring of β-lactams for critically ill patients: unwarranted or essential?

International Journal of Antimicrobial Agents

Volumn 35, Issue 5, 2010, Pages 419-420

  Roberts, Jason A ^a,b   Hope, William W ^b   Lipman, Jeffrey ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFTRIAXONE; DICLOXACILLIN; FLUCLOXACILLIN; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CRITICALLY ILL PATIENT; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG EXPOSURE; DRUG MONITORING; DRUG PROTEIN BINDING; EDITORIAL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INFECTION; INTENSIVE CARE UNIT; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; PATIENT CARE; PHARMACODYNAMICS; PRIORITY JOURNAL; STANDARD;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CRITICAL ILLNESS; DRUG MONITORING; HUMANS;

EID: 77949659592     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.01.022     Document Type: Editorial

References (14)

1. Vincent J.L., Rello J., Marshall J., Silva E., Anzueto A., Martin C.D., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
2. Talbot G.H., Bradley J., Edwards J.E., Gilbert D., Scheld M., Bartlett J.G., et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42:657-668.
3. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
4. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002, 19:349-353.
5. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., Jimenez-Jimenez F.J., Perez-Paredes C., Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31:2742-2751.
6. Garnacho-Montero J., Aldabo-Pallas T., Garnacho-Montero C., Cayuela A., Jiménez R., Barroso S., et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006, 10:R111.
7. Kumar A., Roberts D., Wood K.E., Light B., Parrillo J.E., Sharma S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596.
8. MacArthur R.D., Miller M., Albertson T., Panacek E., Johnson D., Teoh L., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004, 38:284-288.
9. Roberts J.A., Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851.
10. Choi G., Gomersall C.D., Tian Q., Joynt G.M., Freebairn R., Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009, 37:2268-2282.
11. Drusano G.L., Preston S.L., Fowler C., Corrado M., Weisinger B., Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004, 189:1590-1597.
12. Roberts J.A., Kirkpatrick C.M.J., Roberts M.S., Robertson T.A., Dalley A.J., Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150.
13. Roberts J.A., Paratz J., Paratz E., Krueger W.A., Lipman J. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007, 30:11-18.
14. Roos J.F., Bulitta J., Lipman J., Kirkpatrick C.M. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006, 58:987-993.